Peter Riedell to United States
This is a "connection" page, showing publications Peter Riedell has written about United States.
Connection Strength
0.177
-
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.
Score: 0.084
-
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
Score: 0.023
-
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
Score: 0.018
-
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 10; 91(10):1002-7.
Score: 0.014
-
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. J Natl Cancer Inst. 2016 11; 108(11).
Score: 0.014
-
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015 May; 6(3):211-8.
Score: 0.013
-
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014 Dec; 167(5):699-702.
Score: 0.012